Integrating Multiple Inputs Into an Artificial Pancreas System: Narrative Literature Review.
algorithms
control systems
diabetes mellitus, type 1
insulin infusion systems
multivariate analysis
pancreas, artificial
Journal
JMIR diabetes
ISSN: 2371-4379
Titre abrégé: JMIR Diabetes
Pays: Canada
ID NLM: 101719410
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
received:
16
03
2021
accepted:
01
01
2022
revised:
07
06
2021
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
Type 1 diabetes (T1D) is a chronic autoimmune disease in which a deficiency in insulin production impairs the glucose homeostasis of the body. Continuous subcutaneous infusion of insulin is a commonly used treatment method. Artificial pancreas systems (APS) use continuous glucose level monitoring and continuous subcutaneous infusion of insulin in a closed-loop mode incorporating a controller (or control algorithm). However, the operation of APS is challenging because of complexities arising during meals, exercise, stress, sleep, illnesses, glucose sensing and insulin action delays, and the cognitive burden. To overcome these challenges, options to augment APS through integration of additional inputs, creating multi-input APS (MAPS), are being investigated. The aim of this survey is to identify and analyze input data, control architectures, and validation methods of MAPS to better understand the complexities and current state of such systems. This is expected to be valuable in developing improved systems to enhance the quality of life of people with T1D. A literature survey was conducted using the Scopus, PubMed, and IEEE Xplore databases for the period January 1, 2005, to February 10, 2020. On the basis of the search criteria, 1092 articles were initially shortlisted, of which 11 (1.01%) were selected for an in-depth narrative analysis. In addition, 6 clinical studies associated with the selected studies were also analyzed. Signals such as heart rate, accelerometer readings, energy expenditure, and galvanic skin response captured by wearable devices were the most frequently used additional inputs. The use of invasive (blood or other body fluid analytes) inputs such as lactate and adrenaline were also simulated. These inputs were incorporated to switch the mode of the controller through activity detection, directly incorporated for decision-making and for the development of intermediate modules for the controller. The validation of the MAPS was carried out through the use of simulators based on different physiological models and clinical trials. The integration of additional physiological signals with continuous glucose level monitoring has the potential to optimize glucose control in people with T1D through addressing the identified limitations of APS. Most of the identified additional inputs are related to wearable devices. The rapid growth in wearable technologies can be seen as a key motivator regarding MAPS. However, it is important to further evaluate the practical complexities and psychosocial aspects associated with such systems in real life.
Sections du résumé
BACKGROUND
BACKGROUND
Type 1 diabetes (T1D) is a chronic autoimmune disease in which a deficiency in insulin production impairs the glucose homeostasis of the body. Continuous subcutaneous infusion of insulin is a commonly used treatment method. Artificial pancreas systems (APS) use continuous glucose level monitoring and continuous subcutaneous infusion of insulin in a closed-loop mode incorporating a controller (or control algorithm). However, the operation of APS is challenging because of complexities arising during meals, exercise, stress, sleep, illnesses, glucose sensing and insulin action delays, and the cognitive burden. To overcome these challenges, options to augment APS through integration of additional inputs, creating multi-input APS (MAPS), are being investigated.
OBJECTIVE
OBJECTIVE
The aim of this survey is to identify and analyze input data, control architectures, and validation methods of MAPS to better understand the complexities and current state of such systems. This is expected to be valuable in developing improved systems to enhance the quality of life of people with T1D.
METHODS
METHODS
A literature survey was conducted using the Scopus, PubMed, and IEEE Xplore databases for the period January 1, 2005, to February 10, 2020. On the basis of the search criteria, 1092 articles were initially shortlisted, of which 11 (1.01%) were selected for an in-depth narrative analysis. In addition, 6 clinical studies associated with the selected studies were also analyzed.
RESULTS
RESULTS
Signals such as heart rate, accelerometer readings, energy expenditure, and galvanic skin response captured by wearable devices were the most frequently used additional inputs. The use of invasive (blood or other body fluid analytes) inputs such as lactate and adrenaline were also simulated. These inputs were incorporated to switch the mode of the controller through activity detection, directly incorporated for decision-making and for the development of intermediate modules for the controller. The validation of the MAPS was carried out through the use of simulators based on different physiological models and clinical trials.
CONCLUSIONS
CONCLUSIONS
The integration of additional physiological signals with continuous glucose level monitoring has the potential to optimize glucose control in people with T1D through addressing the identified limitations of APS. Most of the identified additional inputs are related to wearable devices. The rapid growth in wearable technologies can be seen as a key motivator regarding MAPS. However, it is important to further evaluate the practical complexities and psychosocial aspects associated with such systems in real life.
Identifiants
pubmed: 35200143
pii: v7i1e28861
doi: 10.2196/28861
pmc: PMC8914747
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28861Informations de copyright
©Chirath Hettiarachchi, Elena Daskalaki, Jane Desborough, Christopher J Nolan, David O’Neal, Hanna Suominen. Originally published in JMIR Diabetes (https://diabetes.jmir.org), 24.02.2022.
Références
Diabetes Educ. 2017 Apr;43(2):223-232
pubmed: 28340542
Diabetes Ther. 2020 Jun;11(6):1217-1235
pubmed: 32356245
J Diabetes Sci Technol. 2010 Jan 01;4(1):132-44
pubmed: 20167177
J Diabetes Sci Technol. 2019 Nov;13(6):1044-1053
pubmed: 31595784
Am J Physiol. 1979 Jun;236(6):E667-77
pubmed: 443421
Curr Diab Rep. 2017 Aug 15;17(10):88
pubmed: 28812204
Sensors (Basel). 2018 Mar 16;18(3):
pubmed: 29547553
Ind Eng Chem Res. 2013 Sep 4;52(35):
pubmed: 24187436
Curr Opin Endocrinol Diabetes Obes. 2021 Feb 1;28(1):1-7
pubmed: 33315628
J Diabetes Sci Technol. 2016 Nov 1;10(6):1236-1244
pubmed: 27464755
IEEE Trans Biomed Eng. 2014 Mar;61(3):883-91
pubmed: 24557689
J Clin Endocrinol Metab. 2001 May;86(5):2118-24
pubmed: 11344216
Horm Metab Res. 1977;Suppl 7:23-33
pubmed: 873440
J Biomech. 2008;41(4):744-52
pubmed: 18206156
Anal Chem. 2020 Jan 21;92(2):2291-2300
pubmed: 31874029
Diabetes Technol Ther. 2014 Aug;16(8):506-11
pubmed: 24702135
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabetes Care. 2020 Aug;43(8):1967-1975
pubmed: 32669412
J Diabetes Sci Technol. 2019 Sep;13(5):967-973
pubmed: 30628470
J Theor Biol. 2010 Mar 7;263(1):154-60
pubmed: 19962391
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Diabetes Technol Ther. 2018 Oct;20(10):662-671
pubmed: 30188192
BMC Endocr Disord. 2018 Feb 20;18(1):12
pubmed: 29458348
J Diabetes Complications. 2015 Jan-Feb;29(1):93-8
pubmed: 25264232
Diabetes Technol Ther. 2013 Nov;15(11):935-41
pubmed: 23978267
J Appl Physiol (1985). 2008 Jun;104(6):1665-73
pubmed: 18403453
Diabetes Care. 2014;37(5):1191-7
pubmed: 24757226
J Diabetes Sci Technol. 2015 Oct 05;9(6):1175-84
pubmed: 26438720
Expert Rev Med Devices. 2013 Sep;10(5):661-73
pubmed: 23972072
Diabetes Care. 2014;37(5):1184-90
pubmed: 24757225
Comput Chem Eng. 2019 Nov 2;130:
pubmed: 32863472
PLoS Med. 2007 Feb;4(2):e69
pubmed: 17326710
J Diabetes Sci Technol. 2018 Mar;12(2):273-281
pubmed: 29451021
Int J Pharm Investig. 2016 Jan-Mar;6(1):1-9
pubmed: 27014614
J Diabetes Sci Technol. 2014 May;8(3):498-507
pubmed: 24876613
JMIR Diabetes. 2021 Feb 2;6(1):e20973
pubmed: 33528374
Diabetes Technol Ther. 2013 May;15(5):386-400
pubmed: 23544672
Diabetes. 2011 Nov;60(11):2672-82
pubmed: 22025773
IEEE Trans Biomed Eng. 2005 Jan;52(1):3-12
pubmed: 15651559
IEEE J Biomed Health Inform. 2016 Jan;20(1):47-54
pubmed: 26087510
J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088
pubmed: 28367636
BMC Endocr Disord. 2018 Oct 13;18(1):71
pubmed: 30316299
Diabetes Technol Ther. 2005 Feb;7(1):28-47
pubmed: 15738702
Endocrinol Metab Clin North Am. 2020 Dec;49(4):667-678
pubmed: 33153673
PLoS One. 2019 Jul 25;14(7):e0217301
pubmed: 31344037
Physiol Meas. 2004 Aug;25(4):905-20
pubmed: 15382830
J Clin Psychol Med Settings. 2017 Mar;24(1):74-81
pubmed: 28280962
Lancet. 2018 Jun 16;391(10138):2449-2462
pubmed: 29916386
Pediatr Diabetes. 2017 Nov;18(7):540-546
pubmed: 27734563
Diabetes Care. 2018 Jul;41(7):1471-1477
pubmed: 29752345
Diabetes Care. 2016 Jul;39(7):1135-42
pubmed: 27289127
JMIR Mhealth Uhealth. 2017 Oct 23;5(10):e124
pubmed: 29061552
J Clin Invest. 1981 Dec;68(6):1456-67
pubmed: 7033284
Sensors (Basel). 2019 Feb 15;19(4):
pubmed: 30781431
Diabet Med. 2018 Apr;35(4):450-459
pubmed: 29337384
J R Soc Med. 2016 Oct;109(10):372-380
pubmed: 27729595
J Diabetes Sci Technol. 2014 Jan 1;8(1):64-69
pubmed: 24876539
J Healthc Eng. 2014;5(1):1-22
pubmed: 24691384
Diabetes Obes Metab. 2016 Nov;18(11):1110-1119
pubmed: 27333970